医療用医薬品 : タケキャブ (タケキャブ錠10mg 他) - KEGG
Oct 23, 2024 · 動物試験（ラット）において、最大臨床用量（40mg/日）におけるボノプラザンの曝露量（AUC）の約28倍を超える曝露量で、胎児体重及び胎盤重量の低値、外表異常（肛門狭窄及び尾の異常）、並びに内臓異常（膜性部心室中隔欠損及び鎖骨下動脈起始異常）が認められている。 治療上の有益性及び母乳栄養の有益性を考慮し、授乳の継続又は中止を検討すること。
Takecab Tablets 10mg : Takeda Pharmaceutical Company …
Certificate of Origin (CoO), Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) of “Takecab Tablets 10mg” are available. *PIL and SmPC are written in Japanese.
Vonoprazan Tablets SMPC
This document provides information on Takecab tablets, including 10mg and 20mg formulations. It describes the drug's approval information, composition, efficacy for treating various conditions like gastric ulcers and helping eradicate Helicobacter pylori infections.
New Drug Application for Oral Disintegrated Tablet Formulation of ...
Mar 22, 2021 · Takeda Pharmaceutical Co., Ltd. (Takeda) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced today that Takeda has applied for approval to manufacture and market TAKECAB ® OD 10 mg and TAKECAB ® OD 20 mg as additional formulations of TAKECAB ® 10 mg and TAKECAB ® 20 mg, developed by Takeda for treating acid-related disease.
Takecab Tablets 20mg [agents for killing Helicobacter
Jan 10, 2020 · BRAND NAME: TAKECAB TABLETS 20MG [AGENTS FOR KILLING HELICOBACTER PYLORI] ACTIVE INGREDIENT: Vonoprazan fumarate DOSAGE FORM: faint red oval tablet, major axis: 11.2 mm, minor axis: 6.2 mm, thickness: 3.9 mm IMPRINT OR PRINT ON WRAPPING: (Face)タケキャブ 20mg, (Back)タケキャブ 20 EFFECTS OF THIS MEDICINE This medicine inhibits the ...
Vonoprazan: First Global Approval | Drugs - Springer
Mar 6, 2015 · Vonoprazan (Takecab ®) is an orally bioavailable potassium-competitive acid blocker (P-CAB) being developed by Takeda for the treatment and prevention of acid-related diseases.
Takecab Tablets 10mg [agents for killing Helicobacter
BRAND NAME: TAKECAB TABLETS 10MG [AGENTS FOR KILLING HELICOBACTER PYLORI] ACTIVE INGREDIENT: Vonoprazan fumarate DOSAGE FORM: faint yellow oval tablet, major axis: 8.2 mm, minor axis: 4.7 mm, thickness: 3.4 mm IMPRINT OR PRINT ON WRAPPING: (Face)タケキャブ 10mg, (Back)タケキャブ 10 EFFECTS OF …
Takecab Tablets 20mg [agents for digestive organ] | myHealthbox
BRAND NAME: TAKECAB TABLETS 20MG [AGENTS FOR DIGESTIVE ORGAN] ACTIVE INGREDIENT: Vonoprazan fumarate DOSAGE FORM: faint red oval tablet, major axis: 11.2 mm, minor axis: 6.2 mm, thickness 3.9 mm IMPRINT OR PRINT ON WRAPPING: (Face)タケキャブ 20mg, (Back)タケキャブ 20 EFFECTS OF THIS MEDICINE This …
Vonoprazan: first global approval - PubMed
Vonoprazan (Takecab (®)) is an orally bioavailable potassium-competitive acid blocker (P-CAB) being developed by Takeda for the treatment and prevention of acid-related diseases.
武田在日本推出新型口服抗胃酸药物Takecab - 梅斯医学 ...
Mar 2, 2015 · 日本制药企业武田（Takeda）及合作伙伴大冢（Otsuka）近日宣布，在日本推出新型口服抗胃酸药物Takecab（vonoprazan fumarate，富马酸沃诺拉赞），用于酸相关疾病的治疗。 Takecab由武田发现，该药属于钾离子（K+）竞争性酸阻滞剂（P-CAB）的新一类抑制剂，具有速效、强劲、持久的胃酸分泌抑制作用；同时，在胃壁细胞胃酸分泌的最后一步中，通过抑制K+对H+,K. 日本制药企业武田（Takeda）及合作伙伴大冢（Otsuka）近日宣布，在日本推出新型口 …